Results 211 to 220 of about 6,410,935 (343)

Design of a highly potent bifunctional HIV-1 entry inhibitor targeting both gp120 and gp41. [PDF]

RSC Med Chem
Du X, Li Q, Du S, Wang H, Shi A, Yuan M, Yu F, Liu Y, Wang C.   +8 more
europepmc   +1 more source

A role for eIF5A in translational control of stress‐inducible proteins in multiple myeloma cell lines

Molecular Oncology, EarlyView.
Loss of eIF5A rewires thapsigargin‐mediated endoplasmic reticulum stress responses in multiple myeloma cells by selective translation of mRNA transcripts, consequently dampening thapsigargin‐induced unfolded protein response (UPR) activation and shifting the balance from induction of apoptosis toward cell survival and proliferation.
Demi Both, Ingrid A. M. Derks, Raphaël Vanleyssem, Marine Leclercq, Najla El Hachem, Pierre Close, Eric Eldering, Marco Vincent Haselager   +7 more
wiley   +1 more source

A Bifunctional SARS-CoV-2 Entry Inhibitor Targeting the Host Protease TMPRSS2 and Viral Spike Protein HR1 Region. [PDF]

Int J Mol Sci
Wang H, Li Q, Yin Z, Du S, Zheng L, Du X, Shi A, Li J, Shi W, Yu F, Xiao J, Wang C.   +11 more
europepmc   +1 more source

Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study. [PDF]

J Biomol Struct Dyn, 2022
Mishra A, Kaur U, Singh A.
europepmc   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source

Coadministration of ribavirin and arenaviral entry inhibitor LHF-535 enhances antiviral benefit against authentic lassa virus. [PDF]

Virol Sin
Peng C, Hu J, Bai Y, Wu W, Mao W, Liu Y, Wan Y, Zhang L, Li W, Tian T, Liu T, Wang Y, Liang M, Han J, Yuan Z, Li J, Shan C, Deng F, Wang W.   +18 more
europepmc   +1 more source

Discovery of Imidazo[1,2-α][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor.

ACS Medicinal Chemistry Letters, 2015
Huang Wang, Shuo Wang, Lili Cheng, Ligong Chen, Yong-Guang Wang, Jie Qing, Shengdian Huang, Yuanhao Wang, Xiaoqiang Lei, Yunfei Wu, Zhi-Long Ma, Lin-Qi Zhang, Yefeng Tang   +12 more
semanticscholar   +1 more source

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source

In vivo affinity maturation of the CD4 domains of an HIV-1-entry inhibitor. [PDF]

Nat Biomed Eng
Pan A, Bailey CC, Ou T, Xu J, Aristotelous T, Liu X, Hu B, Crynen G, Skamangas N, Bronkema N, Tran MH, Mou H, Zhang X, Alpert MD, Yin Y, Farzan M, He W.   +16 more
europepmc   +1 more source

Unobserved Capacity Constraints and Entry Deterrence [PDF]

This paper examines entry deterrence and signaling when an incumbent firm experiences a capacity constraint, arising from either her productive efficiency or the high market demand she faces.
Felix Munoz-Garcia, Gulnara Zaynutdinova
core